Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Large Growth in Short Interest

Capricor Therapeutics Inc (NASDAQ:CAPR) saw a large increase in short interest in December. As of December 15th, there was short interest totalling 5,590,000 shares, an increase of 26.8% from the November 30th total of 4,410,000 shares. Based on an average daily volume of 3,570,000 shares, the short-interest ratio is currently 1.6 days.

Capricor Therapeutics Price Performance

Shares of CAPR stock remained flat at $14.08 during trading on Friday. 774,032 shares of the company traded hands, compared to its average volume of 1,193,585. The business’s fifty day moving average is $17.36 and its 200-day moving average is $10.60. Capricor Therapeutics has a twelve month low of $3.52 and a twelve month high of $23.40. The company has a market capitalization of $640.22 million, a price-to-earnings ratio of -13.28 and a beta of 3.98.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors have recently modified their holdings of CAPR. Main Street Financial Solutions LLC raised its stake in shares of Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Capricor Therapeutics in the 3rd quarter valued at approximately $133,000. Rhumbline Advisers acquired a new position in Capricor Therapeutics in the second quarter worth approximately $147,000. The Manufacturers Life Insurance Company bought a new position in Capricor Therapeutics during the third quarter valued at approximately $161,000. Finally, Sassicaia Capital Advisers LLC acquired a new stake in Capricor Therapeutics in the third quarter valued at approximately $192,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Analysts Set New Price Targets

CAPR has been the topic of several recent research reports. Oppenheimer restated an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Maxim Group boosted their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Cantor Fitzgerald increased their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research note on Thursday, November 14th. Finally, Piper Sandler started coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.